Treatment Patterns and Healthcare Resource Utilization Following Initiation of Aripiprazole Lauroxil Using a 1-Day Initiation Regimen in Patients with Schizophrenia.

ABSTRACT:

Introduction

The long-acting injectable antipsychotic aripiprazole lauroxil (AL) can be initiated in a single day using a one-time injection of a NanoCrystal Dispersion formulation of AL (AL_NCD) and a 30-mg oral dose of aripiprazole. Treatment with AL initiated using AL_NCD significantly improved symptoms of schizophrenia in a phase 3b study. The current study evaluated real-world treatment patterns and healthcare resource utilization (HCRU) among patients with schizophrenia who initiated AL using AL_NCD.

Methods

This retrospective analysis used data from January 1, 2018, to December 31, 2022, derived from Komodo's Healthcare Map™, an administrative claims database. Adults with schizophrenia who initiated AL using AL_NCD and had conti

SUBMITTER: Lauriello J 

PROVIDER: S-EPMC12394314 | biostudies-literature | 2025 Sep

REPOSITORIES: biostudies-literature